Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 extension study of ADX-324 in hereditary angioedema
2025-521353-16-00Phase 3Authorised
- Sponsor
- ADARx Pharmaceuticals
- Start
- Aug 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 21
01
Overview
Phase 3, open-label, single-arm trial of onvuzosiran in hereditary angioedema (HAE), sponsored by ADARx Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Planned start Aug 2026; status: authorised.
02
Drugs
onvuzosiran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2025-521353-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521353-16-00.